

**Proxy for resolutions to be taken in the Extraordinary General Meeting  
of shareholders of Pharming Group N.V.**

Proxy for the Extraordinary General Meeting of shareholders as organised by Pharming Group N.V. (“the Company”) and to be held on March 4, 2025, at 14:00 CET (hereafter also the “EGM”).

**THE UNDERSIGNED:**

\_\_\_\_\_, a company / private person residing at \_\_\_\_\_,  
acting as holder of \_\_\_\_\_ shares in **Pharming Group N.V.**, a public company incorporated and existing under the laws of the Netherlands, having its registered office in Leiden, the Netherlands;

**HEREBY GRANTS FULL PROXY AND POWER OF ATTORNEY TO:**

- Each member of the Board of Directors of the Company; or
- Mr P.C.S. van der Bijl, civil law notary (notaris) at NautaDutilh N.V., or a substitute to be designated by him (the “Notary”).

to represent the undersigned, with the right of substitution, at the EGM and to vote on behalf of the undersigned with regard to any and all matters on the agenda, with all powers that the undersigned would be able to execute if personally attending the EGM, in accordance with the voting instructions as specified at page 2 of this proxy.

This proxy is only valid if (a) duly signed, (b) the undersigned has registered for the EGM in accordance with the procedure set out in the Notice to Convene as published on January 21, 2025 (the “Notice to Convene”) and (c) the undersigned attaches either (i) the registration certificate received from ABN AMRO, or (ii) a written confirmation from its intermediary (as defined in the “Wet Giraal Effectenverkeer”) confirming that the undersigned was a shareholder on the Record Time, or (iii) an Acknowledgement of Receipt for non-traded shares, all as described in the Notice to Convene.

This proxy is subject to the following conditions:

- in the absence of a selection of a proxyholder above, or the name details of a third party proxyholder, the undersigned will be considered to have granted a proxy and power of attorney to the Notary;
- the agenda items are stated in this proxy in abbreviated form; the full agenda as set out in the Notice to Convene, as incorporated herein by this reference, is leading for the interpretation of each agenda item and the proposed resolution;
- if no voting instruction, or a conflicting voting instruction, is given in this proxy for any or all of the items on the agenda, the undersigned shall be deemed to have instructed the proxyholder to vote ‘in favour’ of the relevant agenda item(s) as set out in the Notice to Convene;
- this proxy is governed exclusively by the laws of The Netherlands.

**Voting instructions:**

**In**      **Against**      **Abstain**  
**favour**

<b>Agenda item</b>	<b>Summary</b>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>2</b>	Proposal, by way of binding nomination, to appoint Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a period of four years	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>3.1</b>	Approval of certain components of the remuneration package for Mr. Chouraqui, as new Executive Director and Chief Executive Officer, as further described in the agenda in the Notice to Convene.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>3.2</b>	Authorization of the Board of Directors as the company body authorized (a) to grant and issue to the new Executive Director and Chief Executive Officer (i) the restricted ordinary shares pursuant to the LTI and (ii) the compensation for the forfeited equity awards in shares for the value of forfeited equity by leaving the previous employer, and (b) to exclude any pre-emptive rights in connection with such grant and issue.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Signed in (*place*:) \_\_\_\_\_ on (*date*:) \_\_\_\_\_ 2025

Signature: \_\_\_\_\_

Name: .....